Key takeaways
- Isomorphic Labs announced a $5 billion Series C on November 17, 2026, co-led by Greenoaks and Sequoia Capital.
- Andreessen Horowitz joined as a new investor, and Alphabet, Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund invested again.
- The company gave no valuation and no date for its first clinical trial.
Isomorphic Labs, the Alphabet-backed drug discovery company run by Demis Hassabis, announced a $5 billion Series C round on November 17, 2026. Greenoaks and Sequoia Capital co-led it, with Andreessen Horowitz and other new investors joining. It comes six months after the company's $2.1 billion Series B.
That is a lot of money for a company with no drug in human trials yet. Isomorphic is betting that AI models can design medicines faster and better than the usual trial-and-error lab work, and its investors are paying for that bet before the clinical proof arrives.
Who put money into the Isomorphic Labs Series C
The press release lists:
| Role | Investors |
|---|---|
| Co-leads | Greenoaks, Sequoia Capital |
| New investors | Andreessen Horowitz (a16z) and several others it doesn't name |
| Existing investors | Alphabet, Thrive Capital, MGX, GV, CapitalG, Temasek, the UK Sovereign AI Fund |
The company called the round oversubscribed, meaning investors asked for more than it sold. It did not give a valuation. Bloomberg reported on November 4 that Isomorphic was in talks to raise about $5 billion at a valuation near $50 billion, citing people familiar with the matter. The company has not confirmed that figure.
The jump in size is steep. The Series B in May 2026 raised $2.1 billion, led by Thrive Capital. Bloomberg puts the company's first outside round at $600 million in March 2025.
What the money is for
Isomorphic spun out of Google DeepMind in 2021 and builds on the same line of work as AlphaFold, DeepMind's model that predicts the 3D shape of proteins. Its main product is IsoDDE, its drug design engine. The company describes it as a set of "simulation" models that predict how molecules behave and interact across several disease areas and drug types, plus agents that reason over biological systems.
The release says the money goes to four things:
- Making IsoDDE better and extending its models into new areas of biology.
- Building a network of partners to study how diseases work at the molecular level.
- Building computing infrastructure for what it calls AI-led bioengineering.
- Building the translational and clinical teams and systems it needs to take drug candidates into trials.
Hassabis said the round will help drive "our first therapeutic programs towards clinical trials." The release says internal programs in cancer (oncology) and immune diseases (immunology), and programs with partners, have shown "positive preclinical results", meaning results in lab and animal studies.
What isn't known yet
The release names no drug, no target disease beyond those two broad areas, and no date for a first trial. Preclinical results are the company's own description; it has published no data with this announcement. Most drug candidates that look good before trials fail once they reach people, AI-designed or not.
This is also the gap the money has to close. Isomorphic has now raised more than $7 billion in its last two rounds alone. It has not yet shown that a molecule its models designed works in a patient. The first clinical trial will be the real test, and the release does not say when that will be.
Isomorphic is headquartered in London, with offices in Cambridge, Massachusetts, and Lausanne, Switzerland. Hassabis is its CEO and Max Jaderberg its president.
Sources
- Isomorphic Labs announces Series C investment roundIsomorphic Labs
- Isomorphic Labs announces $5 Billion Series C funding (press release)Isomorphic Labs
- Isomorphic Labs announces Series B investment roundIsomorphic Labs
- Sequoia and Greenoaks lead massive $5BN Series C funding round in Isomorphic LabsTech.eu
- Alphabet's Isomorphic Labs raised a $5B Series C (Bloomberg, via Techmeme)Techmeme



